Similarly, a phase Ib study evaluating the combination of pelareorep, PD-1-targeted ICI pembrolizumab, and standard chemotherapy for the treatment of patients with advanced pancreatic adenocarcinoma revealed that the combination therapy increased number of CD8+ T cells in tumor tissues in 2 out of 7 evaluable patients. The gene discussed is CD8A; the disease is neoplasm.